Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia

American Journal of Cardiology

Volumn 92, Issue 9, 2003, Pages 1113-1116

  Kajinami, Kouji ^a   Takekoshi, Noboru ^a   Matsui, Shinobu ^a   Kanemitsu, Seiyu ^a   Okubo, Shinji ^a   Kanayama, Sugako ^a   Yamashita, Naohiro ^a   Sato, Ryoko ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; COLLAGEN TYPE 1; OSTEOCALCIN; VITAMIN D;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DISEASE MARKER; DRUG EFFECT; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HUMAN; IN VIVO STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 0142227255     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.06.011     Document Type: Article

References (20)

1. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
2. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 283:2000;3205-3210.
3. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in the elderly. JAMA. 283:2000;3211-3216.
4. Chan K.A., Andrade S.E., Boles M., Buist D.S.M., Chase G.A., Donahue J.G., Goodman M.J., Gurwitz J.H., LaCroix A.Z., Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188.
5. Edwards C.J., Hart D.J., Spector T.D. Oral statins and increased bone mineral density in postmenopausal women. Lancet. 355:2000;2218-2219.
6. Chung Y.S., Lee M.D., Lee S.K., Chow C.C., Chan I.H., Lam C.W. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 85:2000;1137-1142.
7. Pederson T.R., Kjekshus J. Statin drugs and the risk of fracture. JAMA. 284:2000;1921-1922.
8. Wada Y., Nakamura Y., Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med. 160:2000;2865.
9. Reid I.R., Hague W., Emberson J., Baker J., Tonkin A., Hung D., MacMahon S., Sharpe N. Effect of pravastatin on frequency of fracture in the LIPID study secondary analysis of a randomized controlled trial. Lancet. 357:2001;509-512.
10. van Staa T.P., Wegman S., de Vries F., Leufkens B., Cooper C. Use of statins and risk of fracture. JAMA. 285:2001;1850-1855.
11. Kajinami K., Yagi K., Higashikata T., Inazu A., Koizumi J., Mabuchi H. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am J Cardiol. 82:1998;113-117.
12. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., Tanaka A., Tada N., Nakamura H., Campos E. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 223:1993;53-71.
13. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
14. Chan M.H., Mak T.W., Chiu R.W., Chow C., Chan I.H., Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab. 86:2001;4556-4559.
15. Mostaza J.M., De la Piedra C., Curiel M.D., Pena R., Lahoz C. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clin Chim Acta. 308:2001;133-137.
16. Watanabe S., Fukumoto S., Takeuchi Y., Fujita H., Nakano T., Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med. 110:2001;584-587.
17. Stein E.A., Farnier M., Waldstreicher J., Mercuri M. Effects of statins on biomarkers of bone metabolism a randomised trial. Nutr Metab Cardiovasc Dis. 11:2001;84-87.
18. Hsia J., Morse M., Levin V. Effect of simvastatin on bone markers in osteopenic women a placebo-controlled, dose-ranging trial. BMC Musculoskelet Disord. 3:2002;7-12.
19. Drissi H., Pouliot A., Koolloos C., Stein J.L., Lian J.B., Stein G.S., van Wijnen A.J. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res. 274:2002;323-333.
20. Tintut Y., Parhami F., Le V., Karsenty G., Demer L.L. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem. 274:1999;28875-28879.